Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
midazolam + rocuronium + fentanyl + propofol
- Development stage
- Phase 4
- Lead developer
- Universidade Estadual Paulista
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This refers to a specific drug combination regimen used for the induction and maintenance of general anesthesia in a clinical study conducted by the Universidade Estadual Paulista Júlio de Mesquita Filho (UNESP). The regimen consists of midazolam (a benzodiazepine for sedation), rocuronium (a non-depolarizing neuromuscular blocking agent), fentanyl (an opioid analgesic), and propofol (an intravenous anesthetic). The study specifically investigates the pharmacokinetics and pharmacodynamics of rocuronium within this anesthetic context, particularly focusing on the effects of sepsis, age, and genetic polymorphisms (such as SLCO1A2) on drug metabolism and action. This combination is typically administered intravenously to achieve a state of unconsciousness, analgesia, and muscle relaxation required for surgical procedures.
- Other names
- General anesthesia (UNESP regimen)
02
Targets
GABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)Nicotinic Acetylcholine ReceptorGABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)
Beyond the preview
Go deeper on midazolam + rocuronium + fentanyl + propofol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on midazolam + rocuronium + fentanyl + propofol.